.Attribute Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view asks for addition of patients with MASLD and also size of liver outcomes in cardio-- renal-- metabolic tests, when data suggest mechanistically probable benefits and also professional safety-- as well as describes points to consider for trial layout as well as governing approval.